Join us for continued coverage of the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, Day 2.

San Antonio Breast Cancer Symposium attendees this week considered evidence that bevacizumab plus chemotherapy may be an effective new option for the treatment of early breast cancer, in a study entitled: Neoadjuvant Chemotherapy with or without Bevacizumab: Primary Efficacy Endpoint Analysis of the GEPARQUINTO Study (GBG 44).

For more information from SABCS 2010, please click here: SABCS 2010.

Produced by The Doctor’s Channel